Related Experiment Video
Updated: May 23, 2026
MicroRNA Based Liquid Biopsy: The Experience of the Plasma miRNA Signature Classifier (MSC) for Lung Cancer Screening
Published on: October 26, 2017
Novel Score Based on miRNA-106 b.5p Expression Signature and Routine Biomarkers for Early Detection of Hepatocellular
Nema Farag1,2, Hani Saleh1,2, Hatem A El-Mezayen1,2
1Cancer Biology Research Unit, Capital University, Cairo, Egypt.
Background And Aim:
Hepatocellular carcinoma (HCC) remains a leading cause of cancer-related mortality, particularly among patients with chronic hepatitis C virus (HCV) infection. The limited sensitivity of current diagnostic tools, including imaging and serum alpha-fetoprotein (AFP), underscores the need for novel biomarkers to enable early detection. This study aimed to assess the diagnostic value of circulating miRNA-106 b.5p and to develop an integrated predictive model combining this marker with routine biochemical parameters for early HCC detection in HCV-infected patients.
Methods:
A total of 42 HCC patients, 83 liver cirrhosis (LC) patients, and 20 healthy controls were enrolled. Serum miRNA-106 b.5p levels were quantified using qRT-PCR, and biochemical markers, including AFP, albumin, platelets, ALT, and bilirubin, were measured. Receiver operating characteristic (ROC) and multivariate discriminant analyses were performed to evaluate diagnostic performance and to construct a combined predictive score.
Results:
Serum miRNA-106 b.5p expression was significantly higher in HCC patients compared with LC patients and controls (p < 0.001), showing a progressive increase along the disease spectrum. ROC analysis revealed miRNA-106 b.5p (AUC = 0.679) outperformed AFP (AUC = 0.731) in discriminating HCC from cirrhosis. The newly developed miRNA-106 b.5p HCC score, integrating miRNA-106 b.5p, AFP, albumin, platelet count, total bilirubin, and ALT, achieved 94% sensitivity and 91% specificity (AUC = 0.744) at a cut-off value of 0.42. The model demonstrated superior performance in detecting early-stage and low-grade tumors compared with AFP alone.
Conclusion:
Integration of miRNA-106 b.5p with routine biochemical markers markedly enhances non-invasive diagnosis of HCV-related HCC. The proposed miRNA-106 b.5p HCC score represents a cost-effective, accurate, and clinically applicable tool for early tumor detection and improved management of high-risk patients.
